Detalles de la búsqueda
1.
Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
Diabetes Obes Metab
; 21(3): 622-630, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30362250
2.
Practical Guidance on Effective Basal Insulin Titration for Primary Care Providers.
Clin Diabetes
; 37(4): 368-376, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31660010
3.
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.
Clin Diabetes
; 37(1): 73-81, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30705500
4.
Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.
Cardiovasc Diabetol
; 17(1): 118, 2018 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30143045
5.
Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
Diabetes Obes Metab
; 20(1): 165-172, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28685973
6.
Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).
Diabetes Obes Metab
; 20(2): 448-452, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-28736942
7.
HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Endocr Pract
; 24(3): 273-287, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29547044
8.
Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.
Clin Diabetes
; 36(2): 149-159, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29686454
9.
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
BMC Endocr Disord
; 17(1): 32, 2017 Jun 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-28595617
10.
Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens.
Diabetes Technol Ther
; 2024 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38758213
11.
Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice.
J Endocr Soc
; 5(9): bvab064, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34291180
12.
GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
Postgrad Med
; 132(sup2): 3-14, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32815454
13.
Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study.
BMJ Open Diabetes Res Care
; 8(1)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33037036
14.
Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study.
Curr Med Res Opin
; 36(2): 219-227, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31625766
15.
Evaluation of the Use of Exenatide Once-Weekly Suspension Autoinjector Among Patients With Type 2 Diabetes Mellitus and Health Care Professionals.
J Diabetes Sci Technol
; 13(2): 226-234, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30234374
16.
Efficacy and tolerability of exenatide once weekly over 7â¯years in patients with type 2 diabetes: An open-label extension of the DURATION-1 study.
J Diabetes Complications
; 33(3): 223-230, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30600137
17.
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
J Diabetes Complications
; 33(2): 140-147, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30554838
18.
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
Curr Med Res Opin
; 34(6): 1125-1133, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29557199
19.
Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.
Postgrad Med
; 129(4): 436-445, 2017 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-28294702
20.
Efficacy and Safety of Multiple Doses of Exenatide Once-Monthly Suspension in Patients With Type 2 Diabetes: A Phase II Randomized Clinical Trial.
Diabetes Care
; 39(10): 1768-76, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27436275